Navigation Links
Onyx Pharmaceuticals to Present at the 2008 Credit Suisse Health Care Conference
Date:11/5/2008

EMERYVILLE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the 2008 Credit Suisse Health Care Conference on Wednesday, November 12, at 10:00 a.m. Mountain Time (9:00 a.m. Pacific Time). Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/wt/page/event_calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through December 12, 2008.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
2. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
3. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
4. Transdel Pharmaceuticals to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference
5. VIA Pharmaceuticals Announces Upcoming Investor Conference Presentations
6. OncoMed Pharmaceuticals Completes Series B Financing
7. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
8. Genesis Pharmaceuticals Launches New Corporate Website
9. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
10. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
11. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., ... of therapeutic antibodies, today announced the advancement ... program into IND-enabling studies. The Company,s anti-IL-36R ... treatment for generalized pustular psoriasis (GPP), an ... medical need. ANB019 is wholly owned within AnaptysBio,s ...
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, an ... improving cancer surgeries, announced today that it has initiated ... illuminator, AVB-620, in women with primary, non-recurrent breast cancer ... also welcomed the addition of Steven Chen , ... The open label, dose escalation study will enroll up ...
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
(Date:4/16/2015)... Fairleigh Dickinson University ( FDU ... become the Executive Director of the Rothman Institute ... kick-off of the Initiative for Patient Centered Innovation ... under the Rothman Institute of Innovation and Entrepreneurship ... collaboration with FDU’s School of Pharmacy’s Center for ...
Breaking Biology Technology:AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... out of the desert floor at a place called Ash Meadows, ... found nowhere else in the world. A new Brigham Young ... completing a 15,000-year journey, flowing slowly underground from what is now ... there for four decades, and a crack in the Earth,s crust ...
... , June 17 On Friday June 11th , ... for the District of Delaware issued an important pre-trial ruling ... , , , ... defined several key phrases contained in Roquette,s patent claims, thereby dealing a ...
... ... have demonstrated its ability to diminish or eliminate tumor load in melanoma, breast cancer, colon ... ... Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown ...
Cached Biology Technology:SPI Pharma Gains Ground in Roquette Patent Dispute 2Human Embryonic-Like Extracellular Matrix Significantly Inhibits Tumor Growth and Cancer Cell Proliferation 2Human Embryonic-Like Extracellular Matrix Significantly Inhibits Tumor Growth and Cancer Cell Proliferation 3
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... fight against the deadly Hendra virus following the development of ... of people who become infected with the virus. ... that administering human monoclonal antibodies after exposure to Nipah virus, ... challenge in a disease model. According to CSIRO,s Dr ...
... SCM Microsystems, Inc. (Nasdaq: SCMM ) (Prime Standard: ... identity and secure exchange, announced today that its stockholders have ... during yesterday,s annual meeting of stockholders. , At ... of SCM,s stockholders cast their votes and a majority followed ...
... that around 2.4 billion years ago, the Earth,s atmosphere ... Called the "Great Oxidation Event" (GOE), the oxygen ... transformation from an oxygen-poor atmosphere to an oxygen-rich one ... the planet. Two questions that remain unresolved in ...
Cached Biology News:Breakthrough in fight against Hendra virus 2SCM Microsystems Announces Results of Annual Meeting 2A new wrinkle in ancient ocean chemistry 2A new wrinkle in ancient ocean chemistry 3
... The Luminex 100 IS System is a ... laboratory that integrates lasers, optics, fluidics, a controller, ... reader. This powerful, compact lab analysis system includes ... SD. Also, it has a DMF file at ...
... Highly nutritious peptone, ... the production of bacterial ... cultivation of bacteria with ... Corynbacterium, Haemophilus, Neisseria, Pasteurella, ...
... A549 cells were cultured in Ham's F12K medium ... log phase of growth. In order to keep ... fixed in acetone-methanol. The cells are arrayed on ... each wells surface specifically treated to enhance cellular ...
Cell Culture Flask, 175 cm, tissue-culture treated polystyrene, barcoded...
Biology Products: